Literature DB >> 30173328

The relationship between quality of life, cognition, and thyroid status in Graves' disease.

Cínthia Minatel Riguetto1, Arnaldo Moura Neto2, Marcos Antônio Tambascia2, Denise Engelbrecht Zantut-Wittmann2.   

Abstract

PURPOSE: To assess quality of life (QoL) and cognitive function among Graves' disease (GD) patients with different thyroid status, with and without ophthalmopathy.
METHODS: This is a cross-sectional clinic-based study involving 154 patients with GD (81.27% were female, mean age 45.6 ± SD 11.2 years) and 54 (35.06%) had ophthalmopathy. Data were collected after an informed consent from all patients was obtained. All patients completed the 36-Item Short Form Health Survey and Mini-Mental State Examination. Patients with ophthalmopathy also completed the Graves' Orbitopathy Quality of Life Questionnaire.
RESULTS: Patients with hyperthyroidism presented a greater impairment in QoL when compared to euthyroidism group. A lower score in physical role functioning was found in both subgroups with active disease (hyperthyroidism and euthyroidism using thionamides). A lower score was also seen in visual function, only in patients with hyperthyroidism, without difference in appearance. No difference was found in cognition between patients. Younger ages at diagnosis, male sex, euthyroidism and absence of ophthalmopathy were factors associated with better QoL, as well as a shorter disease duration was associated with better recall, attention and calculation.
CONCLUSIONS: An impairment in QoL among patients with active GD was evidenced, even in those receiving thionamides and in euthyroidism. Ophthalmopathy was a factor associated with a poor QoL and no clear evidence of cognitive impairment was demonstrated.

Entities:  

Keywords:  Cognitive function; Graves’ disease; Graves’ ophthalmopathy; Hyperthyroidism; Quality of life

Mesh:

Substances:

Year:  2018        PMID: 30173328     DOI: 10.1007/s12020-018-1733-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  12 in total

1.  The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea.

Authors:  So Young Park; Bo Hyun Kim; Mijin Kim; A Ram Hong; Jun Park; Hyunju Park; Min Sun Choi; Tae Hyuk Kim; Sun Wook Kim; Ho-Cheol Kang; Jae Hoon Chung
Journal:  Endocrine       Date:  2021-04-15       Impact factor: 3.633

2.  Commentary: Thyroid eye disease in India: A wake-up call?

Authors:  Bipasha Mukherjee
Journal:  Indian J Ophthalmol       Date:  2020-08       Impact factor: 1.848

3.  Patient-Reported Outcomes Following Total Thyroidectomy for Graves' Disease.

Authors:  Alexander H Gunn; Nicholas Frisco; Samantha M Thomas; Michael T Stang; Randall P Scheri; Hadiza S Kazaure
Journal:  Thyroid       Date:  2021-12-03       Impact factor: 6.568

4.  Reduced cortical complexity in patients with thyroid-associated ophthalmopathy.

Authors:  Jiang Zhou; Wen Chen; Qian Wu; Lu Chen; Huan-Huan Chen; Hu Liu; Xiao-Quan Xu; Fei-Yun Wu; Hao Hu
Journal:  Brain Imaging Behav       Date:  2022-07-12       Impact factor: 3.224

5.  Altered Long- and Short-Range Functional Connectivity Density in Patients With Thyroid-Associated Ophthalmopathy: A Resting-State fMRI Study.

Authors:  Wen-Hao Jiang; Huan-Huan Chen; Wen Chen; Qian Wu; Lu Chen; Jiang Zhou; Xiao-Quan Xu; Hao Hu; Fei-Yun Wu
Journal:  Front Neurol       Date:  2022-06-23       Impact factor: 4.086

6.  Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial.

Authors:  Elena Hoppe; Alan Chun Hong Lee; David Hoppe; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-07-02

7.  Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of 131I during radioiodine therapy of Graves' disease.

Authors:  C Happel; W T Kranert; D Gröner; J Baumgarten; J Halstenberg; B Bockisch; A Sabet; F Grünwald
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

8.  Value of Infrared Thermography Camera Attached to a Smartphone for Evaluation and Follow-up of Patients with Graves' Ophthalmopathy.

Authors:  Cínthia Minatel Riguetto; Walter José Minicucci; Arnaldo Moura Neto; Marcos Antonio Tambascia; Denise Engelbrecht Zantut-Wittmann
Journal:  Int J Endocrinol       Date:  2019-05-09       Impact factor: 3.257

9.  No Effect of Thyroid Dysfunction and Autoimmunity on Health-Related Quality of Life and Mental Health in Children and Adolescents: Results From a Nationwide Cross-Sectional Study.

Authors:  Raphael Hirtz; Anne Keesen; Heike Hölling; Berthold P Hauffa; Anke Hinney; Corinna Grasemann
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-02       Impact factor: 5.555

10.  Development and psychometric properties of the Thai Graves' ophthalmopathy quality of life (GO-QOL) questionnaire.

Authors:  Mingkwan Lumyongsatien; Benjama Keeratidamkerngsakul; Kanokrat Pornpanich; Sumalee Vangveeravong; Preamjit Saonanon; Damrong Wiwatwongwana; Pornchai Mahaisavariya; Orapan Aryasit; Krit Pongpirul
Journal:  J Patient Rep Outcomes       Date:  2019-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.